Published • loading... • Updated
Heart Attack: Antisense Oligonucleotide Is Intended to Prevent Ventricular Remodeling
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Hanover – The antisense oligonucleotide CDR132L, intended to prevent adverse remodeling of the heart muscle (ventricular remodeling) after a heart attack, only partially met expectations in a phase 2 trial in patients with systolic dysfunction. According to the findings presented at the Heart Failure Association congress in...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
